Glutamine and tumor metabolism and their applications in nuclear medicine

Abstract

Liu Fei, Zhu Hua, Lin Xinfeng, Luo Zheng, Li Nan, Yang Zhi. Glutamine and tumor metabolism and their applications in nuclear medicine[J]. Journal of International Oncology, 2015, 42(2): 122-125.

［1］ Koppenol WH, Bounds PL, Dang CV. Otto Warburg′s contributions to current concepts of cancer metabolism［J］. Nat Rev Cancer, 2011, 11(5): 325-337. ［2］ DeBerardinis RJ, Cheng T. Q′s next: the diverse function of glutamine in metabolism, cell biology and cance［J］. Oncogene, 2010, 29(3): 313-324. ［3］ Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology physiology, and clinical opportunities［J］. J Clin Invest, 2013, 123(9): 3678-3684. ［4］ Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer［J］. Trends Biochem Sci, 2010, 35(8): 427-433. ［5］ Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy［J］. Cell, 2009, 136(3): 521-534. ［6］ Jewell JL, Russell RC, GuanKL. Amino acid signaling upstream of mTOR［J］. Nat Rev Mol Cell Biol, 2013, 14(3): 133-139. ［7］ Csibi A, Fendt SM, Li C, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4［J］. Cell， 2013, 153(4): 840-854. ［8］ Qu W, Oya S, Lieberman BP, et al. Preparation and characterization of L［511C］glutamine for metabolic imaging of tumors［J］. J Nucl Med, 2012, 53(1): 98-105. ［9］ Gao P, Tchernyshyov I, Chang TC, et al. cMyc suppression of miR23a/b enhances mitochondrial glutaminase expression and glutamine metabolism［J］. Nature, 2009, 458(7239): 762-765. ［10］ Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?［J］. Semin Cancer Biol, 2005, 15(4): 254-266. ［11］ van den Heuvel AP, Jing J, Wooster RF, et al. Analysis of glutamine dependency in nonsmall cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth［J］. Cancer Biol Ther, 2012, 13(12):1185-1194. ［12］ Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell typespecific glutamine independence in breast epithelia［J］. PLoS Genet, 2011, 7(8): e1002229. ［13］ Wang Q, Beaumont KA, Otte NJ, et al. Targeting glutamine transport to suppress melanoma cell growth［J］. Int J Cancer, 2014, 135(5): 1060-1071. ［14］ Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a Kras regulated metabolic pathway［J］. Nature, 2013, 496(7443): 101-105. ［15］ Hassanein M, Hoeksema MD, Shiota M, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival［J］. Clin Cancer Res, 2013, 19(3): 560-570. ［16］ Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation［J］. Cancer Cell, 2010, 18(3): 207-219. ［17］ Robinson MM, McBryant SJ, Tsukamoto T, et al. Novel mechanism of inhibition of rat kidneytype glutaminase by bis2(5 phenylacetamido1,2,4thiadiazol2yl)ethyl sulfide (BPTES)［J］. Biochem J, 2007, 406(3): 407-414. ［18］ Qing G, Li B, Vu A, et al. ATF4 regulates MYCmediated neuroblastoma cell death upon glutamine deprivation［J］. Cancer Cell, 2012， 22(5): 631-644. ［19］ Thornburg JM, Nelson KK, Clem BF, et al. Targeting aspartate aminotransferase in breast cancer［J］. Breast Cancer Res, 2008, 10(5): R84. ［20］ Robey IF, Stephen RM, Brown KS, et al. Regulationof the Warburg effect in earlypassage breast cancer cells［J］. Neoplasia, 2008, 10(8): 745-756. ［21］ Yu EY, Muzi M, Hackenbracht JA, et al. C11acetate and F18 FDG PET for men ith prostate cancer bone metastases: relative findings and response to therapy［J］. Clin Nucl Med, 2011, 36(3): 192-198. ［22］ Levine AJ, PuzioKuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes［J］. Science, 2010，330(6009): 1340-1344. ［23］ Dinkelborg L, Friebe M, Krasikowa RN, et al. ［18F］ labelled Lglutamic acid, ［18F］ labelled glutamine, their derivatives, their use and processes for their preparation: EP, 1923382［P］. 20080521. ［24］ Kung HF, Thompson CB, Qu WC, et al. Single diastereomers of 4fluoroglutamine and methods for their preparation and use: US, WO2011/020018［P］. 20110217. ［25］ Lieberman BP, Ploessl K, Wang L, et al. PET imaging of glutaminolysis in tumors by 18F(2S,4R)4fluoroglutamine［J］. J Nucl Med, 2011, 52(12): 1947-1955. ［26］ Ploessl K, Wang L, Lieberman BP, et al. Comparative evaluation of 18Flabeled glutamic acid and glutamine as tumor metabolic imaging agents［J］. J Nucl Med, 2012, 53(10): 1616-1624.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Glutamine and tumor metabolism and their applications in nuclear medicine

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments